Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD1656 add-on to metformin in type 2 diabetes mellitus
2009-012612-41Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AZD1656 in type 2 diabetes mellitus (T2DM) (6 arms), sponsored by AstraZeneca. Primary endpoint: Change in HbA1c from baseline to final visit at 4 months. Started Jul 2009; status: completed.
02
Drugs
AZD1656
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2009-012612-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012612-41.